Mode
Text Size
Log in / Sign up
N/A Completed N=173 Randomized

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

Diabetes Mellitus, Type 1 · Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov NCT00928057 ↗
Enrolled (actual)
173
Serious AEs
1.7%
Results posted
Oct 2010
Primary outcomePrimary: Percent (%) Absolute Change in Fructosamine — 5.5; 4.9 Percent absolute change — p=0.506

Summary

Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may appeal to many diabetic patients as the new needle may be perceived as less intimidating and more comfortable. Currently marketed pen needles range in length from 5 to 12.7 millimeters (mm). The primary purpose of this study was to evaluate whether the investigational 4mm x 32 Gauge(G) pen needle manufactured by Becton, Dickinson and Company (BD) provides equivalent glucose control (as measured by fructosamine levels) as the currently marketed BD 5mm x 31 G and BD 8mm x 31 G pen needles (PN)in diabetic subjects with varying insulin dosage regimens.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent (%) Absolute Change in Fructosamine
5.5; 4.9 0.506
SECONDARY
Percent Absolute Change in Fructosamine, by Dose Group
5.5; 5.5; 5.3; 4.2 —
SECONDARY
Number of Subjects With Severe Unexplained Hypoglycemic Events
5; 5; 4 —
SECONDARY
Number of Subjects With Severe Unexplained Hyperglycemic Events
0; 2; 1 —
SECONDARY
Relative Injection Pain Score Assessed by Subject
-23.26; -11.91 0.019 sig

Eligibility Criteria

Inclusion Criteria

  • Insulin requiring diabetics (type 1 or type 2)
  • Using a pen device for injections at least once per day, for at least two months prior to baseline (Study Visit Two).
  • 18 to 75 years of age, inclusive.
  • Body Mass Index from 18 to 50 kg/m², inclusive.
  • Hemoglobin A1c from 5.5 to 9.5 percent (%), inclusive.
  • Largest single dose of insulin a day less than or equal to 40 units

Exclusion Criteria

  • Current status or history of a medical condition that would contraindicate treatment with the study product or other conditions which, in the opinion of the Investigator, would place the subject at risk or have the potential to confound interpretation of the study results (i.e. recent history of ketoacidosis, hypoglycemic unawareness, etc.).
  • Hemophilia or any other disorder which causes excessive bleeding or requires frequent transfusions.
  • History of intravenous drug abuse (self-reported).
  • Bleeding disorder, hemophilia or subject is currently taking anti-coagulant medications (e.g., heparin, Coumadin®, warfarin).
  • Self-reported blood borne infection.
  • Pregnant (from medical history only).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00928057). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search